Erectile dysfunction represents a common problem in the male hypertensive population. Both erectile dysfunction and hypertension share common pathophysiologic pathways such as atherosclerosis and endothelial dysfunction. Furthermore, traditional cardiovascular risk factors affect both conditions. Notably, several antihypertensive medications seem to adversely affect erectile function whereas others may exert neutral or even favorable effects. Thus, the regular and meticulous clinical evaluation of hypertensive patients, as well as individualization of anti-hypertensive therapy, are important steps in the effective management of such patients. In addition, the administration of phosphodiesterase-5 inhibitors or apomorphine has excellent efficacy and safety profile in hypertensive patients irrespective of taking or not taking anti-hypertensive medications.
Get full access to this article
View all access options for this article.
References
1.
NIH consensus development panel on impotence. NIH consensus conference: Impotence. JAMA270:83-90, 1993.
2.
Melman A, Gingell JC: The epidemiology and pathophysiology of erectile dysfunction. J Urol161:5-11, 1999.
3.
Feldman HA, Goldstein I, Hatzichristou DG, et al: Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol151:54-61, 1994.
4.
Johannes CB, Araujo AB, Feldman HA, et al: Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts Male Aging Study. J Urol163:460-463, 2000.
5.
Lechtenderg R, Ohl DA: Effects of aging. In: Sexual Dysfunction, ed. 1, ed. by Lechtenderg R, Ohl DA. Philadelphia: Lea and Febiger, 1994, pp 183-188.
6.
Jensen J, Lendorf A, Stimpel H, et al: The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens12:271-275, 1999.
7.
Della Chiesa A, Pfiffner D, Meier B, et al: Sexual activity in hypertensive men. J Hum Hypertens17:515-521, 2003.
8.
Aranda P, Ruilope LM, Calvo C, et al: Erectile dysfunction in essential arterial hypertension and effects of sildenafil: Results of a Spanish National Study. Am J Hypertens17:139-145, 2004.
9.
Drexler H, Hornig B: Endothelial dysfunction in human disease. J Mol Cell Cardiol31:51-60, 1999.
Sullivan ME, Thompson CS, Dashwood MR, et al: Nitric oxide and penile erection: Is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res43:658-665, 1999.
12.
Maas R, Schwedhelm E, Albsmeier J, et al: The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med7:213-225, 2002.
13.
Saenz de Tejada I, Goldstein I, Azadzoi K, et al: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med320:1025-1030, 1989.
14.
Williams IL, Wheatcroft SB, Shah AM, et al: Obesity, atherosclerosis and the vascular endothelium: Mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord26:754-764, 2002.
15.
Tsiara S, Elisaf M, Mikhailidis DP: Influence of smoking on predictors of vascular disease. Angiology54:507-530, 2003.
16.
Feldman HA, Johannes CB, Derby CA, et al: Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts Male Aging Study. Prev Med30:328-338, 2000.
17.
Grimm RH, Grandits GA, Prineas RJ, et al: Long-term effects on sexual dysfunction of five antihypertensive drugs and nutritional treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension29:8-14, 1997.
18.
Mikhailidis DP, Khan MA, Milionis HJ, et al: The treatment of hypertension in patients with erectile dysfunction. Curr Med Res Opin16(suppl 1):s31-s36, 2000.
19.
Ferrario CM, Levy P: Sexual dysfunction in patients with hypertension: Implications for therapy. J Clin Hypertens (Greenwich)4:424-432, 2002.
20.
Fogari R, Zoppi A: Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep4:202-210, 2002.
21.
Smith PJ, Talbert RL: Sexual dysfunction with anti-hypertensive and antipsychotic agents. Clin Pharm5:373-384, 1986.
22.
Chang SW, Fine R, Siegel D, et al: The impact of diuretic therapy on reported sexual function. Arch Intern Med151:2402-2408, 1991.
23.
Langford HG, Rockhold RW, Wassertheil-Smoller S, et al: Effect of weight loss on thiazide produced erectile problems in men. Trans Am Clin Climatol Assoc101:190-194, 1989.
24.
Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reaction to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet2:539-543, 1981.
25.
Bauer GE, Baker J, Hunyor SN, et al: Side effects of antihypertensive treatment: A placebo-controlled study. Clin Sci Mol Med4(suppl):341s-344s, 1978.
26.
Loriaux DL, Menard R, Taylor A, et al: Spironolactone and endocrine dysfunction. Ann Intern Med85:630-636, 1976.
27.
Suzuki H, Tominaga T, Kumagai H, et al: Effects of first-line antihypertensive agents on sexual function and sex hormones. J Hypertens6(suppl):S649-S651, 1988.
28.
Veterans Administration Cooperative Study Group on Antihypertensive Agents: Propranolol in the treatment of essential hypertension. JAMA88:716-717, 1977.
29.
Burnett WG, Chanine RA: Sexual dysfunction as a complication of propranolol therapy in man. Cardiovasc Med4:811-815, 1979.
30.
Fogari R, Corradi L, Poletti A, et al: Sexual activity in hypertensive males treated with valsartan or carvedilol: A crossover study. Am J Hypertens14:27-31, 2001.
31.
Kolodny RC: Effects of alpha-methyldopa on male sexual function. Sexual Disabil1:223-227, 1987.
32.
Newman RJ, Salerno HR: Sexual dysfunction due to methyldopa. Br Med J4:106, 1974.
33.
Bansal S: Sexual dysfunction in hypertensive men: A critical review of the literature. Hypertension12:1-10, 1988.
34.
Oster JR, Epstein M: Use of centrally acting sympatholytic agents in the management of hypertension. Arch Intern Med151:1638-1644, 1991.
35.
Hogan MJ, Wallin JD, Baer RM: Antihypertensive therapy and male sexual dysfunction. Psychosomatics21:234-237, 1980.
36.
Khan MA, Morgan RJ, Mikhailidis DP: The choice of antihypertensive drugs in patients with erectile dysfunction. Curr Med Res Opin18:103-107, 2002.
Blumentals WA, Brown RR, Gomez-Caminero A: Antihypertensive treatment and erectile dysfunction in a cohort of type II diabetes patients. Int J Impot Res15:314-317, 2003.
Khan MA, Mikhailidis DP, Morgan RJ: Sildenafil: A urologist’s view. Curr Med Res Opin16(suppl 1):s48-s58, 2000.
41.
Brindis RG, Kloner RA: Sildenafil in patients with cardiovascular disease. Am J Cardiol92(suppl):26M-36M, 2003.
42.
Kloner RA, Mitchell M, Emmick JT: Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol92(suppl):47M-57M, 2003.
43.
Webb DJ, Freestone S, Allen MJ, et al: Sildenafil citrate and blood pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol83(suppl):21C-28C, 1999.
44.
Kloner RA, Brown M: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens14:70-73, 2001.
45.
Heaton JP: Characterising the benefit of apomorphine SL (Uprima) as an optimised treatment for representative populations with erectile dysfunction. Int J Impot Res13(suppl 3):S35-S39, 2001.
46.
Heaton JP: Key issues from the clinical trials of apomorphine SL. World J Urol19:25-31, 2001.
47.
Fagan TC, Buttler S, Marbury T, et al: Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Am J Cardiol88:760-766, 2001.
